GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanghai Haoyuan Chemexpress Co Ltd (SHSE:688131) » Definitions » YoY EPS Growth

Shanghai Haoyuan Chemexpress Co (SHSE:688131) YoY EPS Growth : 275.00% (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai Haoyuan Chemexpress Co YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Shanghai Haoyuan Chemexpress Co's YoY EPS Growth for the quarter that ended in Mar. 2025 was 275.00%.

Shanghai Haoyuan Chemexpress Co's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was ¥0.30.


Shanghai Haoyuan Chemexpress Co YoY EPS Growth Historical Data

The historical data trend for Shanghai Haoyuan Chemexpress Co's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Haoyuan Chemexpress Co YoY EPS Growth Chart

Shanghai Haoyuan Chemexpress Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 89.59 27.80 -11.30 -35.79 57.38

Shanghai Haoyuan Chemexpress Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -63.80 9.17 218.18 460.00 275.00

Shanghai Haoyuan Chemexpress Co YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Shanghai Haoyuan Chemexpress Co's YoY EPS Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EPS Growth (A: Dec. 2024 )
=(Earnings per Share (Diluted) (A: Dec. 2024 )-Earnings per Share (Diluted) (A: Dec. 2023 ))/ | Earnings per Share (Diluted) (A: Dec. 2023 ) |
=(0.96-0.61)/ | 0.61 |
=57.38 %

Shanghai Haoyuan Chemexpress Co's YoY EPS Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EPS Growth (Q: Mar. 2025 )
=(Earnings per Share (Diluted) (Q: Mar. 2025 )-Earnings per Share (Diluted) (Q: Mar. 2024 )) / | Earnings per Share (Diluted) (Q: Mar. 2024 )) |
=(0.3-0.08)/ | 0.08 |
=275.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Haoyuan Chemexpress Co YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Shanghai Haoyuan Chemexpress Co's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Haoyuan Chemexpress Co Business Description

Traded in Other Exchanges
N/A
Address
No. 2, Lane 720, Cailun Road, Room 501, Pilot Free Trade Zone, Shanghai, CHN, 201203
Shanghai Haoyuan Chemexpress Co Ltd focuses on providing small molecule and new modalities CDMO services for both pharmaceutical and biotech clients. The company's comprehensive CRO & CDMO platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. It is a one-stop service platform to support client's projects from early drug discovery, process development to commercialization. The company is committed to delivering high-quality products and CMC services to clients across the entire life cycle of drug development.
Executives
Mei Kui Core technical personnel

Shanghai Haoyuan Chemexpress Co Headlines

No Headlines